Published in Cancer Res Treat on March 31, 2009
Nanocarriers for delivery of platinum anticancer drugs. Adv Drug Deliv Rev (2013) 1.11
Progression-free survival and time to progression as surrogate markers of overall survival in patients with advanced gastric cancer: analysis of 36 randomized trials. Invest New Drugs (2011) 0.83
Advances in drug delivery system for platinum agents based combination therapy. Cancer Biol Med (2015) 0.75
Reporting results of cancer treatment. Cancer (1981) 28.83
Cancer statistics, 2001. CA Cancer J Clin (2001) 11.73
Cancer statistics, 2002. CA Cancer J Clin (2002) 10.79
Drugs five years later. Cisplatin. Ann Intern Med (1984) 3.69
Synthesis and antitumor activity of a series of [2-substituted-4,5-bis(aminomethyl)-1,3-dioxolane]platinum(II) complexes. J Med Chem (1994) 2.89
Platinum nephrotoxicity. Am J Med (1978) 1.73
Preclinical studies identifying carboplatin as a viable cisplatin alternative. Cancer Treat Rev (1985) 1.15
A phase II study of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas. J Clin Oncol (1986) 1.03
Kinetics of cis-dichlorodiammineplatinum. Clin Pharmacol Ther (1979) 1.01
Cisplatin and platinum analogues: recent advances. Curr Opin Oncol (1992) 1.01
Cisplatin/carboplatin cross-resistance in ovarian cancer. Br J Cancer (1989) 1.01
Chemotherapy for advanced gastric cancer: slow but further progress. Cancer Res Treat (2005) 0.95
Antitumor activity of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2- isopropyl-1,3-dioxolane]platinum(II), a new platinum analogue, as an anticancer agent. Cancer Chemother Pharmacol (1995) 0.92
Preclinical antitumor and toxicologic profile of carboplatin. Cancer Treat Rev (1985) 0.91
Phase II study of protracted infusional 5-fluorouracil combined with cisplatinum for advanced gastric cancer: report from the Japan Clinical Oncology Group (JCOG). Eur J Cancer (1994) 0.91
Phase II clinical trial of SKI-2053R, a new platinum analog, in the treatment of patients with advanced gastric adenocarcinoma. Cancer (1999) 0.90
Nephrotoxicity of heptaplatin: a randomized comparison with cisplatin in advanced gastric cancer. Cancer Chemother Pharmacol (2002) 0.88
Influence of exposure and infusion times on the cytotoxicity and pharmacokinetics of cis-malonato[(4R, 5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane]platinum(II) . Cancer Chemother Pharmacol (1998) 0.87
Combination chemotherapy with 5-fluorouracil and heptaplatin as first-line treatment in patients with advanced gastric cancer. J Korean Med Sci (2004) 0.83
Pharmacokinetics and antitumor activity of a new platinum compound, cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1, 3- dioxolane]platinum(II), as determined by ex vivo pharmacodynamics. Cancer Chemother Pharmacol (1995) 0.82
Platinum and other metal coordination compounds in cancer chemotherapy. A commentary on the sixth international symposium: San Diego, California, 23-26th January 1991. Br J Cancer (1991) 0.80
In vitro antitumor activity of a new platinum complex, cis-malonato [(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane] platinum (II) (SKI 2053R), against human lung and stomach cancer cell lines. Anticancer Res (1995) 0.78
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol (2008) 23.93
Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol (2013) 3.71
Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol (2011) 2.89
Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia. Nat Genet (2012) 2.26
Sonic hedgehog pathway promotes metastasis and lymphangiogenesis via activation of Akt, EMT, and MMP-9 pathway in gastric cancer. Cancer Res (2011) 1.97
The 5p15.33 locus is associated with risk of lung adenocarcinoma in never-smoking females in Asia. PLoS Genet (2010) 1.90
Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res (2011) 1.89
Chemotherapy use and associated factors among cancer patients near the end of life. Oncology (2007) 1.80
Sonic hedgehog signaling promotes motility and invasiveness of gastric cancer cells through TGF-beta-mediated activation of the ALK5-Smad 3 pathway. Carcinogenesis (2008) 1.74
Kyphoplasty for the treatment of vertebral compression fractures in a cancer patient with neurological deficits and anterior vertebral wall destruction. Pain Physician (2011) 1.61
Prospective clinical study of surgical resection followed by CHOP in localized intestinal diffuse large B cell lymphoma. Leuk Res (2006) 1.60
Association of a vascular endothelial growth factor gene 936 C/T polymorphism with breast cancer risk: a meta-analysis. Breast Cancer Res Treat (2010) 1.50
Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine. J Clin Oncol (2012) 1.45
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial. Eur J Cancer (2012) 1.45
Pilot trial of yttrium-90 ibritumomab tiuxetan consolidation following rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone chemotherapy in patients with limited-stage, bulky diffuse large B-cell lymphoma. Leuk Lymphoma (2011) 1.43
Which patients benefit from preoperative chemoradiotherapy for intermediate staged rectal cancer? Onkologie (2011) 1.42
Inclusion of hemoglobin level in prognostic score provides better prognostic stratification in patients with acute promyelocytic leukemia (APL). Int J Hematol (2013) 1.39
Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL). J Hematol Oncol (2012) 1.37
FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood (2006) 1.36
Multiple myeloma with myelomatous pleural effusion: a case report and review of the literature. Acta Haematol (2008) 1.35
BMP2 accelerates the motility and invasiveness of gastric cancer cells via activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway. Exp Cell Res (2009) 1.27
Do-not-resuscitate orders for terminal patients with cancer in teaching hospitals of Korea. J Palliat Med (2007) 1.25
Gastric leptomeningeal carcinomatosis: multi-center retrospective analysis of 54 cases. World J Gastroenterol (2009) 1.24
Clinical outcomes of patients with liver cirrhosis who underwent curative surgery for gastric cancer: a retrospective multi-center study. Dig Dis Sci (2007) 1.21
Measurement of tumor volume by PET to evaluate prognosis in patients with head and neck cancer treated by chemo-radiation therapy. Acta Oncol (2010) 1.21
Mitochondrial ribosomal protein L41 suppresses cell growth in association with p53 and p27Kip1. Mol Cell Biol (2005) 1.21
Extranodal marginal zone B-cell lymphomas of mucosa-associated lymphoid tissue-type of the orbit and ocular adnexa. Ann Hematol (2004) 1.17
Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study. Haematologica (2010) 1.16
Metastatic function of BMP-2 in gastric cancer cells: the role of PI3K/AKT, MAPK, the NF-κB pathway, and MMP-9 expression. Exp Cell Res (2011) 1.16
The attitudes of cancer patients and their families toward the disclosure of terminal illness. J Clin Oncol (2004) 1.15
Prevalence and characteristics of anemia in the elderly: cross-sectional study of three urban Korean population samples. Am J Hematol (2004) 1.14
Safety and effectiveness of central venous catheterization in patients with cancer: prospective observational study. J Korean Med Sci (2010) 1.12
Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study. Eur J Cancer (2013) 1.12
Acute fibrinous and organizing pneumonia following hematopoietic stem cell transplantation. Korean J Intern Med (2009) 1.12
Increase of NKG2D ligands and sensitivity to NK cell-mediated cytotoxicity of tumor cells by heat shock and ionizing radiation. Exp Mol Med (2006) 1.12
A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia. Blood (2011) 1.11
Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with non-squamous non-small cell lung cancer. Eur J Cancer (2013) 1.09
RASSF1A suppresses the c-Jun-NH2-kinase pathway and inhibits cell cycle progression. Cancer Res (2005) 1.08
Drug resistance to 5-FU linked to reactive oxygen species modulator 1. Biochem Biophys Res Commun (2007) 1.08
Trends of mortality and cause of death among HIV-infected patients in Korea, 1990-2011. J Korean Med Sci (2013) 1.08
Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer. Am J Clin Oncol (2013) 1.07
Experiences and attitudes of patients with terminal cancer and their family caregivers toward the disclosure of terminal illness. J Clin Oncol (2010) 1.05
Phase II trial of gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas. Cancer Chemother Pharmacol (2007) 1.04
Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation. Biol Blood Marrow Transplant (2009) 1.03
Relationship between urokinase-type plasminogen receptor, interleukin-8 gene expression and clinicopathological features in gastric cancer. Oncology (2004) 1.03
A case of Wernicke's encephalopathy following fluorouracil-based chemotherapy. J Korean Med Sci (2009) 1.03
A novel protein, Romo1, induces ROS production in the mitochondria. Biochem Biophys Res Commun (2006) 1.02
Treatment outcomes with CHOP chemotherapy in adult patients with hemophagocytic lymphohistiocytosis. J Korean Med Sci (2008) 1.01
Prognostic stratification of high-risk gastrointestinal stromal tumors in the era of targeted therapy. Ann Surg (2008) 1.01
Complementary and alternative medicine in the undergraduate medical curriculum: a survey of Korean medical schools. J Altern Complement Med (2012) 1.00
A case of bone marrow necrosis with thrombotic thrombocytopenic purpura as a manifestation of occult colon cancer. Jpn J Clin Oncol (2004) 0.99
Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial. Cancer Chemother Pharmacol (2009) 0.98
Case Report of Pulmonary Sarcoidosis Suspected to be Pulmonary Metastasis in a Patient with Breast Cancer. Cancer Res Treat (2014) 0.97
Causes of death and risk factors for mortality among HIV-infected patients receiving antiretroviral therapy in Korea. J Korean Med Sci (2013) 0.97
Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer? Clin Cancer Res (2008) 0.97
Mitochondrial ribosomal protein L41 mediates serum starvation-induced cell-cycle arrest through an increase of p21(WAF1/CIP1). Biochem Biophys Res Commun (2005) 0.97
Interleukin-10 gene polymorphism influences the prognosis of T-cell non-Hodgkin lymphomas. Br J Haematol (2007) 0.97
Impact of awareness of terminal illness and use of palliative care or intensive care unit on the survival of terminally ill patients with cancer: prospective cohort study. J Clin Oncol (2011) 0.97
Multiple myeloma in Korea: past, present, and future perspectives. Experience of the Korean Multiple Myeloma Working Party. Int J Hematol (2010) 0.96
Helicobacter pylori infection as an independent prognostic factor for locally advanced gastric cancer patients treated with adjuvant chemotherapy after curative resection. Int J Cancer (2011) 0.96
Potential prognostic significance of p185(HER2) overexpression with loss of PTEN expression in gastric carcinomas. Tumori (2006) 0.96
Clinical outcome of gastric cancer patients with bone marrow metastases. Cancer Res Treat (2011) 0.95
A multi-center, late phase II clinical trial of Genexol (paclitaxel) and cisplatin for patients with advanced gastric cancer. Oncol Rep (2004) 0.95
Low expression of Bax predicts poor prognosis in patients with locally advanced esophageal cancer treated with definitive chemoradiotherapy. Clin Cancer Res (2007) 0.95
Prognostic significance of immunohistochemical expression of EGFR and C-erbB-2 oncoprotein in curatively resected gastric cancer. Cancer Res Treat (2004) 0.95
A phase II study of epirubicin, cisplatin and capecitabine combination chemotherapy in patients with metastatic or advanced gastric cancer. Oncology (2005) 0.95
Issues and controversies of hepatocellular carcinoma-targeted therapy clinical trials in Asia: experts' opinion. Liver Int (2010) 0.95
The CHEK2 1100delC mutation is not present in Korean patients with breast cancer cases tested for BRCA1 and BRCA2 mutation. Breast Cancer Res Treat (2008) 0.94
Meningeal relapse in a patient with acute promyelocytic leukemia: a case report and review of the literature. J Korean Med Sci (2004) 0.94
Increased expression of ICAM-3 is associated with radiation resistance in cervical cancer. Int J Cancer (2005) 0.94
The oral iron chelator deferasirox induces apoptosis in myeloid leukemia cells by targeting caspase. Acta Haematol (2011) 0.94
Treatment outcome of front-line systemic chemotherapy for localized extranodal NK/T cell lymphoma in nasal and upper aerodigestive tract. Leuk Lymphoma (2006) 0.93
Multidrug resistance-1 gene polymorphisms associated with treatment outcomes in de novo acute myeloid leukemia. Int J Cancer (2006) 0.93
Serum vascular endothelial growth factor per platelet count in hepatocellular carcinoma: correlations with clinical parameters and survival. Jpn J Clin Oncol (2004) 0.93
Early imatinib-mesylate-induced hepatotoxicity in chronic myelogenous leukaemia. Acta Haematol (2007) 0.93
Prevalence of BRCA1 and BRCA2 mutations in Korean breast cancer patients. J Korean Med Sci (2004) 0.93
A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutations. Lung Cancer (2011) 0.93
Economic burdens and quality of life of family caregivers of cancer patients. Oncology (2005) 0.93
Phase II study with a combination of epirubicin, cisplatin, UFT, and leucovorin in advanced hepatocellular carcinoma. Cancer Chemother Pharmacol (2005) 0.93
Upregulation of haptoglobin in reactive astrocytes after transient forebrain ischemia in rats. J Cereb Blood Flow Metab (2002) 0.92
Human placenta-derived feeders support prolonged undifferentiated propagation of a human embryonic stem cell line, SNUhES3: comparison with human bone marrow-derived feeders. Stem Cells Dev (2007) 0.92
Prognostic implications of the immunophenotype in biphenotypic acute leukemia. Leuk Lymphoma (2008) 0.92
Baseline patient characteristics, incidence of CINV, and physician perception of CINV incidence following moderately and highly emetogenic chemotherapy in Asia Pacific countries. Support Care Cancer (2014) 0.92
Graphene oxide as a multi-functional p-dopant of transparent single-walled carbon nanotube films for optoelectronic devices. Nanoscale (2012) 0.92